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Abstract	  	  
Objective: The aims of this study were to test the individual association of the 5-HTT, 
BDNF, and GABRA6 genes with anxiety-related traits and to explore putative GxG 
interactions in a healthy sample. Method: A sample of 937 individuals from the general 
population completed the TCI questionnaire; a subsample of 553 individuals also filled 
in a brief version of the NEO inventory. The whole sample was genotyped for the 5-
HTTLPR polymorphism (5-HTT gene), the Val66Met polymorphism (BDNF gene) and 
the T1521C polymorphism (GABRA6 gene). Results: Individuals carrying the 
TTgenotype of the T1512C polymorphism presented slightly higher scores for Harm 
Avoidance ( HA ) than C allele carriers (F=2.96, p=0.051). In addition, there was a 
significant GxG interaction on HA between the 5-HTTLPR and Val66Met 
polymorphisms (F=3.4, p=0.009). Conclusion: GABRA6 emerges as a putative gene 
may be involved in the variability of HA. The effect of a significant GxG interaction 
between the 5-HTT and BDNF genes on HA could explain part of the genetic basis 
underlying anxiety-related traits.  
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Significant outcomes 
 
• A complex gene–gene interaction between the 5-HTT and BDNF genes explained 
some of the variability in the harm avoidance dimension. 
 
• Genetic variability related to the gabaergic system is associated with the harm 
avoidance dimension in a sample of the Spanish general population. 
 
• The harm avoidance dimension of the TCI questionnaire is more strongly supported 
by genetic components than the neuroticism dimension of the NEO inventory. 
 
Limitations 
 
• The two Spanish populations analyzed presented differences with respect to the 
genotype distribution of the Val66Met polymorphism (BDNF gene). 
 
• Neuroticism data from the NEO inventory were only available for the sample 
from Castelló. 
  
Introduction 
 
Anxiety-related traits that are continuously distributed in the normal human personality 
(1) have been described as individual differences in emotional reactivity, proneness to 
worry and susceptibility to negative affect. They are mainly captured by the presence of 
neuroticism (2, 3) or harm avoidance (4). Neuroticism (N) includes traits such as 
anxiety, anger, hostility, depression, self-consciousness, impulsiveness and 
vulnerability, while harm avoidance (HA) characterizes individuals with high scores for 
being cautious, tense, apprehensive, fearful, inhibited, shy, easily fatigued and worried. 
Both N and HA have been considered as markers for vulnerability to depressive 
disorders (5-8). 
 
Twin studies have suggested that the estimated heritability for personality traits ranges 
between 30 and 50% (9). Specifically, these studies on the genetics of personality have 
demonstrated that the genetic component of anxiety-related traits accounts for 40 to 
60% of the observed variance (10, 11). 
 
There is growing interest in the idea that neurotransmitter functions relate to normal 
variations in personality traits (12, 13). In this sense, serotonin neurotransmission (5-
HT) has a fundamental role in the modulation of emotional behaviour and in brain 
development. Genetic variability associated with 5-HT function is likely to influence 
behavioural predispositions such as anxiety-related traits (14, 15).The serotonin 
transporter (5-HTT) has a key role in 5-HT neurotransmission, since it is the main 
reuptake mechanism and the main biological target for antidepressant drugs. 5-HTT is 
encoded by the SLC6A4 gene, which contains an insertion/deletion in the 5’ promoter 
region of 44bp (5-HTTLPR), with reduced transcription of the 5-HTTLPR short (S) 
allele in comparison with the long L allele (16, 17). 
 
The seminal study carried out by Lesch and collaborators (1996) showed an association 
between anxiety-related traits and the 5-HTT gene (17). Although inconsistencies have 
emerged as shown in a recent meta-analysis (see review (18, 19)), one recent meta-
analyses have shown the definite effect of variability at 5-HTT gene on depression and 
stress sensitivity (20). 
 
Besides the 5-HTT gene, the brain-derived neurotrophic factor (BDNF) from the 
neurotrophin family could be of special interest because of its critical role in normal 
adaptive responses to stress as well as in the response to antidepressant treatment (21, 
22). The BDNF gene (chromosome 11p14) presents an SNP (196 G/A -Val 66 Met) 
located in the 5’ pro-BDNF precursor peptide sequence that may affect intracellular 
processing and secretion of the mature protein (23). Sen et al. (2003) reported that the 
Met allele was associated with lower levels of neuroticism (24), although later studies 
failed to replicate such findings (25-27). Recently, the Met allele of the Val66Met 
polymorphism at the BDNF gene has been shown to play a putative role in anxiety 
disorders. Met carriers showed impaired learning of cues that signal safety versus threat 
that rely on extinction mechanisms (28) . 
 
Another neurotransmitter that might be involved in the propensity for a fearful or 
anxious temperament is γ-aminobutyric acid (GABA), the main inhibitory 
neurotransmitter in the CNS (29, 30). The inhibitory effect of GABA is mediated by 
GABAA receptors, which are ionotropic GABA-gated chloride channel receptors. 
GABA acts as an agonist by inducing conformational changes in the GABAA receptor, 
increasing the permeability of the central pore to chloride ions. The chloride influx 
hyperpolarizes the neuron, reducing its excitability and having a general inhibitory 
effect on neuronal activity. In addition, benzodiazepines, one of the pharmacological 
treatments for anxiety disorders, increase the efficiency of inhibitory GABAergic 
neurotransmission by means of agonists binding to the receptor GABAA. 
 
It has been suggested that individual differences in the frontal cortical GABAA receptor 
complex and GABA systems could modulate patterns of brain activity associated with 
individual differences in threat-related responses (29). Uhart and collaborators (2004) 
analysed a single-nucleotide polymorphism (SNP) consisting of a T-to-C substitution 
(position 1521) in the 3’ non-coding region of the GABAAα6 receptor subunit gene 
GABRA6 (cr. 5q34) in a healthy population (31). The results revealed that 
homozygotes for the C allele showed an attenuated hormonal and physiological 
response to acute psychological stress. Therefore, this polymorphism could be involved 
in the individual differences underlying part of the biological basis of anxiety-related 
traits. 
 
Materials and Methods 
 
Sample 
 
Our sample consisted of 937 subjects from the general population (47.8% males; total 
mean age=30.5, SD=12.2) who were recruited from the campus of the University Jaume 
I (Castelló, Spain) and from primary care settings from Oviedo (Asturias, Spain). 
 
In terms of education 12.2% of individuals had completed elementary school, 56.8% 
had completed high school, and 25% had received a university education. 
Sociodemographic data divided by the geographic origin of the samples 
(Castelló/Asturias) are displayed in Table 1. 
 
 
 
Exclusion criteria were the presence of any past or present major psychiatric disorder 
and/or a history of any severe mental disorder in first-degree relatives. These aspects 
were screened by means of a short interview designed ad hoc for this study on the basis 
of selected items of structured scales such as SCID-I (32) and FIGS (33). All 
participants were of Spanish (Caucasian) ancestry to reduce the possibility of 
confounding genetic differences by population stratification (34). 
 
Ethical approval was obtained from local Spanish research ethic committees in each 
Institution. All participants provided written informed consent before inclusion in the 
study. 
 
Measurements 
 
Personality assessment 
 
All participants filled out the self-reported Temperament and Character Inventory 
(TCI;(35)) composed of 240 items. Given the aims of this study, the analyses focused 
on the dimension of Harm Avoidance (HA), which has four subscales: Anticipatory 
worry (HA1), Fear of uncertainty (HA2), Shyness with strangers (HA3) and Fatigability 
(HA4). Good psychometric properties have been described for TCI (35). 
 
In addition, 533 individuals completed the Brief Big Five Questionnaire (BFQ; (36)). 
This test has high test-retest reliability and longitudinal stability (37). The analyses 
focused on the dimension of Neuroticism (N). Subscales corresponding to the N 
dimension were not available. 
 
Laboratory methods 
 
Genomic DNA from the Castelló subsample was extracted from saliva samples using 
the Collection Kit BuccalAmp DNA extraction kit (Epicentre® Biotechnologies, 
Madison, WI) and that from the Oviedo subsample was extracted from blood samples 
using the salting-out technique (38). The 5-HTTLPR polymorphism of the serotonin 
transporter gene was analyzed using the protocol previously described by Lesch and 
collaborators (1996) (17). The SNP rs6265 (Val66Met) of the BDNF gene and the SNP 
rs3219151 (T1521C) of the GABRA6 gene were genotyped using Applied Biosystems 
(AB) TaqMan technology. An AB assay-on-demand service supplied the probes. 
 
Those individuals who were not genotyped were not included in the final statistical 
analyses (see Table 2 for final sample). 
 
Random individuals were re-genotyped in order to confirm the reproducibility of the 
pattern. 
 
Statistical analyses 
 
Analyses were performed using STATA 9.1 (39) and EpiInfo (40). 
 
 The main effects of polymorphisms on harm avoidance and neuroticism were analyzed 
separately for each of the following polymorphisms: the 5-HTTLPR genotype, BDNF 
genotype, and GABRA6 genotype using linear regression analysis. Regressions were 
performed for the harm avoidance dimension and separately for each individual 
subscale of harm avoidance. The Wald test was performed to test the overall main effect 
of each polymorphism on each dimension and subscale. 
 
The xi3 command was then used to test interactive effects with categorical predictors 
(41). The interactive effects between SLC6A4 5-HTTLPR and BDNF Val66Met, 
between SLC6A4 5-HTTLPR and GABRA6, and between BDNF Val66Met and 
GABRA6 T1512C were fitted in models of harm avoidance and neuroticism. The Wald 
test was used to assess the interaction effect. When a two-way interaction was 
significant, further simple effects were assessed, that is, the effect of VI1 at each level 
of VI2. 
 
All regression analyses were controlled for age, gender and demographic origin. 
 
Results 
 
The genotype, allele distribution and Hardy-Weinberg equilibrium of each population 
(Castelló and Oviedo) as well as those of the total sample are shown in Table 2. 
 
 
 
The genotypic frequencies that we observed in these Spanish populations were similar 
to those frequencies described for European Caucasians (26, 31, 42, 43). 
 
The two populations presented similar genotype and allele distributions for the 5-
HTTLPR polymorphism (5-HTT gene) and for the T1512C polymorphism (GABRA6 
gene). However, the genotype and allele distribution differed between Castelló and 
Oviedo for the Val66Met polymorphism (BDNF gene) (genotype frequencies: 
χ2=11.83, df=2, p=0.003; allele frequencies: χ2=11.93, df=1, p<0.001). These 
differences were taken into account when we merged the samples for subsequent 
statistical analyses. 
 
We found no significant associations between the 5-HTTLPR (5-HTT gene) or 
Val66Met (BDNF gene) polymorphisms and HA or its subscales. 
 
The effect of GABRA6 T1512C polymorphisms on HA approached statistical 
significance, that is, the TT group had higher scores for HA than TC or CC subjects 
(F=2.96, p=0.051). In addition, a significant main effect of the GABRA6 T1512C 
polymorphism was found on HA1 (Anticipatory worry) (F=4.07; p=0.017). 
Specifically, the TT group had higher scores compared to TC or CC. No significant 
effect was found on the other subdimensions (see Table 3). 
 
 
 
Gene and anxiety-related trait interactions 
 
We found a significant two-way interaction in relation to HA. An interaction between 
the 5-HTTLPR and BDNF Val66Met polymorphisms modulated the HA scores (F=3.4, 
p=0.009). Analysis of simple effects showed that subjects with Met/Met and S/S 
genotypes had higher scores on HA compared to Met/Met-LS or Met/Met-LL (F=3.43, 
p=0.033) (see Figure 1). No other two-way interactions were significant with regards to 
HA. 
 
 
 
We found no association between either of the polymorphisms analyzed and N, or any 
gene–gene interaction effect on N. 
 
Discussion 
 
With regards to the main effect of the 5-HTTLPR polymorphism (5-HTT gene) on 
anxiety-related traits, we did not succeed in replicating the previously reported 
association between the S allele and high anxiety-related traits reported by Lesch et al. 
(1996) (17). In contrast, our results agree with most of the studies that have reported 
negative results in Caucasian populations (44-51). 
 
It has been suggested that important sources of heterogeneity between studies could be 
due to the use of slightly different personality constructs, the inclusion of psychiatric 
populations, or the use of small sample sizes (52). In the present study, both neuroticism 
and harm avoidance were explored; in addition, the whole sample was screened for any 
current or lifetime psychiatry disorder and, finally, the sample size was larger than in 
previous studies (44-51). 
 
The Val66Met polymorphism (BDNF gene) has previously been associated with 
anxiety-related traits by Sen et al. (2003) (24). The study revealed that Val allele 
carriers presented higher levels of neuroticism compared to Met allele carriers. 
However, later studies, in agreement with our findings, did not detect this independent 
effect in relation to those personality traits (25-27). 
 
Interestingly, a gene–gene interaction was detected between the 5-HTTLPR 
polymorphism (5-HTT gene) and Val66Met polymorphism (BDNF gene): among 
individuals with the Met/Met genotype, carriers of the SS genotype exhibited 
significantly higher scores for harm avoidance than L allele carriers. This gene–gene 
interaction may underlie the inconsistencies found in studies exploring only the main 
effects of one of these genes and anxiety-related traits. 
 
The results of our study provide evidence for a role of the GABRA6 T1512C 
polymorphism in harm avoidance variability in a large sample from the general 
population. Specifically, the TT genotype of this polymorphism seemed to be strongly 
associated with high scores on the subscale “anticipatory worry” (HA1). These results 
together with the results reported by Uhart et al. (2004)(31) suggest that the GABRA6 
T1512C polymorphism, in accordance with our hypothesis, is strongly associated with 
individual differences in anxiety-related traits, specifically in those traits that are closely 
related to the anxiety spectrum, such as anticipatory worry. However, we know that this 
polymorphism located at 3’ region do not seem to display functional relevance. As ɑ6 
subunit is included into a cluster in chromosome 5q with ɑ1, β2 and ɑ2 subunit genes 
(53), the analyzed polymorphism may be in linkage disequilibrium with another site 
within the GABRA6 gene or these genes located in close proximity. Moreover, GABAA 
receptors are classified as ionotropic receptors which are involved in fast events in the 
neuron, as opposite to other type of receptors (such 5-HTT transporter) that mediate 
more long-term effects modifying the responsiveness and plasticity of the neuron (54). 
We could hypothesized that subtle genetic changes in this fast-response receptors such 
as this SNP, may alter the signal transmission in the neuron impacting, then, in the final 
anxiety related-phenotype. 
 
Finally, our results seem to identify genetic components involved in harm avoidance, 
derived from Cloninger’s tridimensional theory of personality. However, negative 
results were found for the neuroticism dimension derived from the Big Five model 
developed by Costa and McCrae. These results are consistent with a recent metaanalysis 
reporting the existence of a small, but significant genetic background for the harm 
avoidance dimension but not for the neuroticism dimension (19). Taken together, these 
findings suggest that the HA construct seems to be more strongly associated with 
genetically related traits than the neuroticism construct. Nevertheless, further research is 
needed to elucidate the complex biological and genetic architecture of anxiety-related 
traits. 
 
Our study has some limitations. Firstly, we found differences between the Castelló and 
Oviedo populations with respect to the genotype distribution of the Val66Met 
polymorphism (BDNF gene); these differences were basically related to an increase in 
the frequency of the Val/Val genotype in the subsample from Oviedo. However, when 
we merged the two populations, the genotype frequencies were similar to those 
expected in a Caucasian population (26). Thus, it is unlikely that the significant results 
obtained were due to a bias in the genotype distribution. In fact, the effect of interaction 
between 5-HTT and BDNF on HA was found with the Met allele and not with the Val 
allele, as might be expected due to the overrepresentation of this allele in the Oviedo 
sample. 
 
With a sample of almost a thousand individuals, our study was larger tan previous 
studies (44-51), and therefore the likelihood of Type I or II errors was reduced. 
However, some of our findings might not have been statistically significant if multiple 
testing corrections had been carried out. These corrections are likely to be excessively 
exclusive in the context of the present study since the selection of the genetic 
polymorphisms, the sample size and the analyses performed had a directional 
hypothesis based on previous findings (55). 
 
In conclusion, the GABRA6 T1512C polymorphism has emerged as a putative genetic 
factor involved in human anxiety-related trait variability, specifically HA. Moreover, 
the effect of a significant GxG interaction between the 5-HTT gene and BDNF gene on 
HA could partly explain some of the inconsistencies found in previous studies and 
should be taken into account in the understanding of individual differences in complex 
constructs such as anxiety-related traits. 
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